Kornimate/medical-research-clean huggingface dataset:
evaluation of validity and reliability of the turkish translation of the digital health readiness questionaire in different chronic diseases

Conditions: Non-Communicable Chronic Diseases; Survey and Questionnaire; Validation Studies; Digital Health

Summary: the world health organization (who) defines digital health as the field of knowledge and application related to any aspect of the adoption of digital technology in the stages of improvement. the combination of digital health with technology brings about a new transformation in digital media. this transformation allows for the development of communication and information in health services, the ability to conduct health-related research on digital media and the evaluation of this data. the ease of access to information and the provision of a timely feedback mechanism in the face of problems have enabled the spread of digital health systems, and have also enabled chronic disease management and epidemic disease monitoring. it is recommended that the term digital readiness be used to cover the combination of digital access and use, digital literacy and digital health literacy. digital health readiness is also defined as the main determinant of health and is thought to contribute to the improvement of health processes with the development of digital health literacy and to be a useful solution against health problems that may arise in the follow-up of chronic diseases. although there are tools in the literature that evaluate digital health readiness, there is no turkish assessment tool that facilitates the follow-up of non-communicable chronic diseases. therefore, the aim of our study is to evaluate the translation, validity, and reliability of the digital health readiness questionaire into turkish in individuals with chronic non-infectious diseases.


Eligibility criteria:
inclusion criteria: * the study will include people over the age of 18, native turkish speakers, literate, obese, diabetic, cardiovascular and respiratory patients. exclusion criteria: * individuals with insufficient cooperation (mini mental test score \&lt;24) and any cognitive problems that may prevent the administration of the survey will be excluded from the study.

Keywords: digital health digital health readiness questionaire
firefighter thermoregulatory responses in active fire with betaine supplementation

Conditions: Body Temperature Changes; Body Water Dehydration; Inflammation

Summary: the goal of this clinical trial is to compare betaine supplementation to placebo in firefighters undergoing live burn training regarding thermoregulation and inflammation. the main questions it aims to answer are: * does betaine supplementation mitigate rises in core temperature during firefighter live burn training? * does betaine supplementation decrease inflammation from firefighter training? * does betaine supplementation increase total body water stores? participants will supplement with betaine for 1 month and complete: * total body water measures * body composition measures * live burn training with core temperature measurements * provide salivary samples


Eligibility criteria:
inclusion criteria: * structural firefighter exclusion criteria: * • participants have a cardiometabolic disease for which they take prescribed medications * participants consume supplements known to impact hydration status or performance that they are not willing to stop taking for the study * participants are pregnant * female participants that have irregular menstrual cycles * participants are injured and would not be able to fulfill the live burn scenario * participants have sickle cell disease * participants have experienced heat stroke within the last 2 years
solstice: combination therapy for the treatment of chronic hepatitis d infection.

Conditions: Hepatitis D, Chronic

Summary: this is a phase 2 trial in which participants with chronic hepatitis d virus (hdv) infection will receive vir-2218 and/or vir-3434 and be assessed for safety, tolerability, and efficacy

participants may be enrolled into cohort 1 (1a and 1b) or cohort 2 (2a, 2b1 or 2b2, 2c), 3, 4, and 5.

Eligibility criteria:
inclusion criteria: * male or female ages 18 to \< 70 years at screening * chronic hdv infection for \>/= 6 months * on nrti therapy for at least 12 weeks prior to day 1 * alt\>uln and \< 5x uln * anti-hbs \>10 miu/ml at screening if only adding a select set of ec * non-cirrhotic and cpt-a cirrhotic exclusion criteria: * any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation. * history of significant liver disease from non-hbv or non-hdv etiology * history of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients. * history of anaphylaxis * history of immune complex disease * history of autoimmune disorder * history or evidence of alcohol or drug abuse * prior or concomitant therapy with an immunomodulatory agent, ifn-alpha, cytotoxic or chemotherapeutic agent, or chronic corticosteroids.

Keywords: hdv hepatitis d virus hepatitis chronic hepatitis d virus
a french multi-centric atrial fibrillation catheter ablation survey

Conditions: Observation of Outcome After Catheter Ablation of Atrial Fibrillation

Summary: atrial fibrillation is the most frequent sustained arrhythmia. catheter ablation is a procedure that is currently used for the treatment of symptomatic atrial fibrillation patients. we have organized a multi-centric national survey of catheter ablation of atrial fibrillation in order to have a feedback on the type of procedures being performed and the overall results (freedom of atrial fibrillation) over an average follow-up of 18 months.


Eligibility criteria:
inclusion criteria: * all patients undergoing catheter ablation of atrial fibrillation or left atrial flutter exclusion criteria: * patients undergoing catheter ablation of other types of arrhythmia

Keywords: atrial fibrillation; catheter ablation; relapse; stroke; death
efficacy, safety, and adequacy of eus-guided liver biopsy

Conditions: Chronic Hepatic; Liver Diseases

Summary: the purpose of this study is to evaluate the efficacy, safety, and adequacy of eus-guided liver biopsy in patients undergoing eus-guided liver biopsy at methodist dallas medical center (mdmc).

the purpose of this study is to evaluate the efficacy, safety, and adequacy of eus-guided liver biopsy in patients undergoing eus-guided liver biopsy at methodist dallas medical center (mdmc). this is a clinical quality improvement (cqi) initiative to evaluate outcomes within our institution. the data collected will be used to inform new innovative ways to improve eus-guided liver biopsy with an ultimate goal of improving the quality of patient care. the clinical outcomes of this patient population have not been previously systematically reviewed in mdmc. currently, the procedure in not being performed routinely at methodist dallas medical center (mdmc). however, with new technical and physician expertise, this option is now available at our institution. pi will evaluate the efficacy, safety, and adequacy of eus-guided liver biopsy in patients requiring histologic examination of their liver at mdmc.

Eligibility criteria:
inclusion criteria: * age 18 years or older * undergone eus-guided liver biopsy at mdmc exclusion criteria: * below 18 years of age * did not undergo eus-guided liver biopsy at mdmc
evaluation of somatostatin receptor imaging using pet/mri as a novel approach to detecting pathology in pulmonary tb

Conditions: Tuberculosis

Summary: imaging using 68ga-dotanoc pet (positron emission tomography) has the potential to detect granulomas in pulmonary tuberculosis, leading to previously unexplored indications for this pet tracer, including identification of subclinical disease in latently infected individuals. this study aims to assess the ability of 68ga-dotanoc pet/mri to detect pulmonary lesions in individuals with active pulmonary tuberculosis.

granulomas, the hallmark of tuberculosis (tb) infection, have an increased density of somatostatin receptors. somatostatin analog pet tracers, such as 68ga-dotanoc, may be able to identify these pulmonary granulomas. although currently used for other medical indications, 68ga-dotanoc pet scanning has not previously been used to detect tb lesions. this is a pilot study which aims to assess the ability of 68ga-dotanoc pet/mri to detect pulmonary lesions in individuals with active pulmonary tuberculosis. the 68ga-dotanoc pet scan and 'standard' 18f-fludeoxyglucose (fdg) pet scan will be compared to enable analysis of differences in uptake between these tracers in terms of number, size and distribution of lesions. demonstrating the clinical utility of 68ga-dotanoc in active pulmonary tb is necessary prior to using this pet tracer to further explore other potential uses in tb such as identifying individuals with latent tb who are at risk of progressing to active tb, measuring therapeutic response to tb treatment and identifying extrapulmonary lesions.

Eligibility criteria:
inclusion criteria: 1. age 21 years and above 2. willing to comply with the study visits and procedures 3. willing and able to provide written informed consent 4. clinical diagnosis of pulmonary tb with characteristic symptoms and compatible x-ray findings plus microbiological confirmation with one or more of (i) acid fast bacilli (afb) smear-positive or (ii) molecular test positive or (iii) tb culture positive 5. not on tb treatment or have completed less than 28 days of tb treatment exclusion criteria: 1. diabetes that is, in the judgment of the investigator, so poorly controlled that it would prevent adequate pet scanning 2. cardiac pacemaker, aneurysm clip or other metallic implant considered unsafe for mri 3. known chronic kidney disease 4. occupation involving substantial exposure to radiation 5. malignancy requiring chemotherapy or radiation 6. women who are currently pregnant or breastfeeding
the effect of a pharmacist home visit on drug-related problems post-discharge.

Conditions: Adverse Drug Event; Readmission; Patient Compliance

Summary: the purpose of this study is to determine the the effect of a home-based medication management program on drug-related problems post-discharge.

inaccuracy of medication histories and lack of knowledge on actual medication use results in confusion about medication regimens and medication mismanagement before- during - and after hospital admission. this phenomenon accounts for many readmissions, longer duration of admission and preventable and serious adverse drug events (ades) as a result of drug related problems (drps). several studies show that discharge medication reconciliation (mr) and counseling by a pharmacy employee reduces the amount of discrepancies in the discharge prescription lists. still, no unequivocal effect of mr on the occurrence of drps after discharge has been shown. this is due to a shift in underlying potential harmful discrepancies from mainly patient based (unintended nonadherence) to mainly system based (eg dispensing errors) and might be explained by (1) suboptimal transfer of information (2) an overload of information during a stressful situation and (3) difficulty to implement changes in medication at home. therefore the reduction of drps, improvement of patients' medication knowledge and initial adherence can probably most effectively be addressed in a multifaceted integrated transmural intervention. repetition of important information is the key to success. moreover, the first weeks following hospital discharge are most crucial in preventing drug-related problems as patients could slip back in old medication schemes, or new problems may arise, such as emerging ades due to medication changes made during hospitalization.

Eligibility criteria:
inclusion criteria: * patient uses more than three prescribed systemic drugs intended for chronic use at admission and discharge * patient has an expected length of stay of 48 hours or longer exclusion criteria: * patients admitted for scheduled chemotherapy * patients admitted for radiation therapy * patients admitted for transplantation * patients transferred from another hospital * patients transferred from another non-eligible ward within the same hospital * no informed consent signed * a live expectancy less than 6 months * inability to be counselled (e.g. cognitive dysfunction, language constraints who cannot be solved with an interpreter) * discharge to a nursing home (presuming dependence on medication administration) * if patients' community pharmacy is not participating in this study

Keywords: continuity of care medicines management home visit drug-related problems
optimization of obesity for total knee replacement with glucagon-like peptide-1 receptor agonist

Conditions: Osteoarthritis (OA) of the Knee

Summary: studies have shown that obese patients undergoing total knee replacement (tkr) surgery face a higher risk of perioperative issues such as increased use of pain medication, surgical site infections, and the need for revision surgeries compared to non-obese patients. obesity is also linked to more significant preoperative pain and lingering symptoms post-surgery. consequently, there's a growing interest in weight loss interventions prior to tkr to enhance perioperative care and outcomes. recent retrospective studies have indicated that such interventions can improve physical function post-tkr. research focusing on weight loss interventions before joint replacement surgery is limited. there is currently a gap in research regarding rcts on weight loss interventions using anti-obesity drugs before tkr, particularly in asian populations. one promising avenue under exploration involves the use of glucagon-like peptide 1 receptor agonists (glp-1ras) as anti-obesity medication before total knee replacement (tkr) surgery. however, there are currently no randomized controlled trials (rcts) examining the effects of glp-1ras on knee arthroplasty outcomes. large database studies have indicated that glp-1ras may decrease the likelihood of certain post-surgery complications but increase the risk of others. in summary, addressing obesity through weight loss interventions, particularly with glp-1ras, holds promise for improving outcomes in tkr patients. however, further research, including randomized controlled trials, is necessary to fully understand the effects of glp-1ras on perioperative outcomes and patient health.

2.1 hypothesis hypothesis for this pilot trial is conducting trial of glp-1ra for perioperative optimization for tkr feasible. the null hypothesis for the full trial is that clinical, functional and quality of life (qol) outcomes in obese patients undergoing tkr will not be improved if this is preceded by glp-1 ra induced weight loss. 3. study objective the primary aims of this pilot study are 1) estimate adherence, tolerability and follow-up rates, 2) recruitment and management challenges. the secondary aims are to assess the effect of semaglutide for perioperative optimization in tkr and gather data to estimate the feasibility like tolerability and sample size for a future trial.

Eligibility criteria:
inclusion criteria: * age between 40 and 80 years old * bmi ≥27 kg/m2 * on the surgical waiting list for primary tkr * willing and able to cooperate in a weight management programme. * meeting indication for semaglutide exclusion criteria: * revision surgery or surgery for neoplastic disease * a medical condition which in the opinion of the investigators makes the patient unsuitable for participation in the trial * contraindication to glp-1ra, like history of pancreatitis, severe gastrointestinal diseases such as gastroparesis, thyroid cancer, and inflammatory bowel disease * lack of acceptance of the randomisation process.

Keywords: osteoarthritis
the effects of subgingival air-polishing, as an adjunct to non-surgical periodontal treatment on periodontal parameters and patient satisfaction in patients with periodontitis

Conditions: Periodontal Diseases

Summary: periodontal disease is serious and global chronic disease. the prevalence of periodontal diseases in united arab emirates is not clear but data from dubai health authority showed that one in five patients has received periodontal treatment in recent years. several studies reported the additional benefits provided by the use of air-polishing devices in combination with ultrasonic debridement in the treatment of gum disease, their use may reduce postoperative pain and discomfort while providing improvement in gum status. the aim of the study is to compare the effect of removing bacterial deposit (biofilm) from deep tooth pocket using combined air-polishing and conventional pocket debridement versus conventional pocket debridement alone on tooth supporting tissue parameters in patients with advanced gum disease (periodontitis). methodology: a total of 22 patients with advanced gum disease will be randomly allocated to two groups: a control group, which will receive conventional pocket debridement and a test group which will receive ultrasonic debridement with air-polishing (airflow prophylaxis master, ems, nyon, switzerland). gum measurements will be recorded by a masked calibrated examiner at six points for each tooth and patients' postoperative experience and satisfaction will be assessed using special forms.


Eligibility criteria:
inclusion criteria: * aged 18 or over. * diagnosed with unstable generalised periodontitis, stage iii-iv and grade b or c. * good compliance and commitment to attend follow-up review appointments. * absence of systemic disease that will may affect the treatment outcome. * willing to provide informed consent. exclusion criteria: * received periodontal treatment in the last 12 months. * received systemic anti-inflammatory or antibiotic in the last 6 months or during the study period. * use of medication known to affect the gingival growth. * chronic bronchitis. * asthma. * participants that require prophylactic antibiotic. * pregnant or breastfeeding participants
the role of tegaserod therapy in the management of dyspeptic symptoms in female patients on proton pump inhibitors for the treatment of heartburn.

Conditions: Dyspepsia

Summary: study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (ppi's) for heartburn.


Eligibility criteria:
inclusion criteria: * female patients 18 years or older. * self-reported presence of symptoms consistent with dyspepsia (including mid-upper abdominal discomfort characterized by post prandial fullness, early satiety and bloating) * stable dose ppi therapy of at least 4 weeks exclusion criteria: * history of intestinal obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or of abdominal adhesions. * evidence that the dyspeptic symptoms are relieved by defecation and/or associated with a change in frequency or stool form. * with a current most bothersome symptom of heartburn. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: dyspepsia hearburn female ppi
evaluate safety and efficacy of paricalcitol in reducing serum intact parathyroid hormone in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: evaluate safety and efficacy of paricalcitol in reducing serum intact parathyroid hormone in chronic kidney disease

evaluate the safety and efficacy of paricalcitol injection with two different dosing regimens (currently approved dosing regimen used in the us package insert versus dosing based on a formula of ipth/80 that was approved and used in the eu package insert) in chronic kidney disease (ckd) stage 5 subjects with secondary hyperparathyroidism receiving hemodialysis.

Eligibility criteria:
inclusion criteria: 1. subject is a chinese male or female greater than or equal to 20 years old. 2. subject is diagnosed with chronic kidney disease stage 5 and must be on maintenance hemodialysis three times a week for at least 2 months prior to the screening visit and expected to remain on hemodialysis for the duration of the study. 3. for entry into the treatment phase, the subject must have: * intact parathyroid hormone greater than or equal to 300 pg/ml * serum calcium less than 10.2 mg/dl (2.55 mmol/l) * calcium-phosphorus product less than 65 mg\^2/dl\^2 exclusion criteria: 1. subject has a history of an allergic reaction or significant sensitivity to vitamin d or vitamin d related compounds. 2. subject received a partial parathyroidectomy within one year prior to the screening phase. 3. subject with new york heart association (nyha) class iii or iv. 4. subject has taken aluminum-containing phosphate binders for greater than 3 weeks in the last 3 months prior to the screening phase, or requires such medications for greater than 3 weeks in the study. 5. subject has a current malignancy (with the exception of basal or squamous cell carcinoma of the skin), or clinically significant liver disease, in the opinion of the investigator. 6. subject has a history of drug or alcohol abuse within 6 months prior to the screening phase. 7. subject is known to be human immunodeficiency virus (hiv) positive. 8. subject has evidence of poor compliance with diet, medication or hemodialysis that may interfere, in the investigator's opinion, with adherence to the protocol.

Keywords: chronic kidney disease secondary hyperparathyroidism